Clear Creek Financial Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Clear Creek Financial Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-459	Closed	-$354K	–	641
2025 Q4	$354K	Sell	459 -147	-24%	-$99.8K	0.03%	460
2025 Q3	$340K	Hold	606	–	–	0.03%	449
2025 Q2	$318K	Buy	+606	New	+$338K	0.03%	428
2023 Q2	–	Sell	-1,047	Closed	-$860K	–	339
2023 Q1	$860K	Buy	1,047 +57	+6%	+$43K	0.16%	112
2022 Q4	$714K	Buy	990 +66	+7%	+$48.7K	0.16%	122
2022 Q3	$637K	Sell	924 -7	-0.8%	-$4.41K	0.14%	125
2022 Q2	$550K	Buy	931 +69	+8%	+$44.9K	0.12%	146
2022 Q1	$602K	Sell	862 -59	-6%	-$37.3K	0.09%	166
2021 Q4	$582K	Sell	921 -623	-40%	-$383K	0.09%	173
2021 Q3	$934K	Buy	1,544 +363	+31%	+$225K	0.15%	132
2021 Q2	$660K	Buy	+1,181	New	+$598K	0.1%	160
2020 Q3	–	Sell	-583	Closed	-$363K	–	222
2020 Q2	$363K	Buy	+583	New	+$331K	0.09%	155

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Clear Creek Financial Management's REGN Position: Q1 2026 in Review

Clear Creek Financial Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 459 shares — an estimated $354K sold.

Clear Creek Financial Management first reported a position in REGN in Q2 2020 and held it in 12 quarters. The position peaked at $934K in Q3 2021. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Clear Creek Financial Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Clear Creek Financial Management sold 459 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $354K.
Clear Creek Financial Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 12 quarters.
Clear Creek Financial Management's Regeneron Pharmaceuticals position peaked at $934K in Q3 2021.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Clear Creek Financial Management's 13F filing for Q1 2026, filed 23 Apr 2026.